Navigation Links
Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
Date:4/25/2011

MALVERN, Pa., April 25, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release results for the first quarter 2011 on Monday, May 9, 2011 before the opening of the U.S. financial markets. The Company will also conduct a conference call that day at 10:00 a.m. ET to discuss results and highlights of the first quarter 2011.  The presentation slides to be used during the call will be available on the "For Investors" section of the Company's web site under the "Presentations" tab beginning at 7 a.m. ET on Monday, May 9, 2011.  A web cast of the conference call and the presentation slides will be available on the "For Investors" section of the Company's web site under the "Events" tab beginning at 10:00 a.m. ET on Monday, May 9, 2011.  A question and answer session will follow the presentation.  

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

Mr. Armando Anido, Chief Executive Officer and President, will host the conference call.Conference call details: Date:

Monday, May 9, 2011Time:

10:00 a.m. ETDial-in (U.S.):

866-314-4483Dial-in (International):

617-213-8049Web cast:

http://www.auxilium.com Passcode:

AUXILIUMTo access an audio replay of the call:Access number (U.S.):

888-286-8010Access number (International):

617-801-6888Replay Passcode #:

77302853About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists. Auxilium markets XIAFLEX® (collagenase clostridium histolyticu
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
2. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
3. CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011
4. Zacharon Pharmaceuticals Announces Research and Development Collaboration With Pfizer to Develop Drugs for Multiple Rare Disorders
5. Meda to License Elidel to Valeant Pharmaceuticals
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Lexicon Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
8. Reportlinker Adds Upstream Processing in Biopharmaceuticals - Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market
9. Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
10. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
11. VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... RESEARCH TRIANGLE PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability , ... drought and insect pressures , Syngenta ... grand opening celebration today at the company’s RTP Innovation ... Crop Lab allows company researchers to simulate any agricultural ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
(Date:5/17/2013)... May 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased ... with Switzerland -based Kenta Biotech ... monoclonal antibody (mAb) products, and technologies. This asset ... for treatment of infections by common pathogens including ... , Pseudomonas aeruginosa , Acinetobacter baumannii ...
(Date:5/17/2013)... May 17, 2013 Men’s skin is biologically ... La-roche Posay ) and has been known to react more ... men may be far from puberty, other acne causing factors ... causing breakouts, and threatening skin with unsightly acne scars. Adult ... Men’s Health on how to reduce and prevent ...
Breaking Biology Technology:Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2
... A new Hospital Energy Performance Service ... energy efficiency by 25% or more ... low-cost modifications. The service is available from ... Massachusetts-based environmental and engineering consulting firm."Healthcare facilities are heavy energy ...
... particle (VLP) vaccine progresses with study designed to select ... Novavax, Inc. (Nasdaq: NVAX ) announced ... trial of its virus-like particle (VLP) seasonal influenza vaccine. ... II randomized, placebo controlled clinical trial has been designed ...
... May 5 Novagali Pharma, a French,pharmaceutical ... New Drug Application (IND) to conduct a ... the treatment of glaucoma has been,granted by ... Catioprost(R) is a,topical ocular proprietary BAK-free formulation ...
Cached Biology Technology:New Hospital Energy Performance Service Helps Hospitals Cut Energy Costs by 25% or More 2Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 2Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 3Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 4Novagali Pharma Announces FDA Clearance of IND for Phase III of Catioprost(R), its Cationic Emulsion of Latanoprost in Patients With Glaucoma 2
(Date:5/17/2013)... An international team of scientists ... and cell movement inside a living frog embryo in ... new method to advance biological research and the search ... University and the Karlsruher Institut fr Technologie in Germany, ... U.S. Department of Energy,s Argonne National Laboratory, released the ...
(Date:5/16/2013)... a fast food restaurant had a higher body mass ... fast food, according to researchers at The University of ... particularly strong among those with a lower income. ... American Journal of Public Health indicates higher BMI ... and among lower-income African-Americans, the density, or number, of ...
(Date:5/16/2013)... layer lining the body,s blood vessels, is extremely ... thickness, this super-tenuous structure routinely withstands blood flow, ... a unique and highly dynamic barrier that maintains ... body,s circulatory system. , It,s also extremely adaptable. ... breached to enable immune cells to reach ...
Breaking Biology News(10 mins):New X-ray method shows how frog embryos could help thwart disease 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... time, scientists have identified an ant species that produces ... , Stanford University biologist Deborah M. Gordon and her ... of the journal Nature. The discovery was made during ... Megan E. Frederickson in the Amazon jungle of western ...
... been the gold standard for treating newborns suffering from ... are superior to sedatives for treating infants born to ... Opiates appear to better "ameliorate the withdrawal, facilitate feeding ... two new systematic reviews done by David Osborn, a ...
... ?"blue gold" on the international deep sea floor ... new report from the Japan-based United Nations University ... as important to humankind for their potential medical ... more accessible and vulnerable than ever because of ...
Cached Biology News:Ants, not evil spirits, create devil's gardens in the Amazon rainforest, study finds 2Ants, not evil spirits, create devil's gardens in the Amazon rainforest, study finds 3Ants, not evil spirits, create devil's gardens in the Amazon rainforest, study finds 4Opiates Better Than Sedatives For Treating Newborns In Withdrawal 2A Father’s Day Gift: Free DNA Paternity Testing 2A Father’s Day Gift: Free DNA Paternity Testing 3A Father’s Day Gift: Free DNA Paternity Testing 4A Father’s Day Gift: Free DNA Paternity Testing 5
Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Biology Products: